Andrew Wiele
University of Texas MD Anderson Cancer Center
Internal medicineOncologyHealth careLenvatinibChemotherapyRenal cell carcinomaBevacizumabErlotinibSafety netMalignancyEverolimusRenal medullary carcinomaGemcitabineDoxorubicinCoronavirus disease 2019 (COVID-19)Dose reductionIn patientImmune checkpoint inhibitorsOverall survivalMedical emergencyGeneral surgeryMedicinePandemic
10Publications
3H-index
2Citations
Publications 14
Newest
#1Robert Hester (University of Texas MD Anderson Cancer Center)H-Index: 2
#2David Stone (University of Texas Health Science Center at Houston)H-Index: 1
Last. Tejal Patel (University of Texas MD Anderson Cancer Center)H-Index: 11
view all 9 authors...
94Background: Increasingly, dedicated clinics have been established to expedite patients with suspicion of malignancy into cancer care. The Lyndon B. Johnson General Hospital (LBJGH) is part of the...
Source
#1Robert Hester (University of Texas MD Anderson Cancer Center)H-Index: 2
#2Lindsey Leigh Farmer (University of Texas Health Science Center at San Antonio)
Last. Christina S. Haddad (University of Texas Health Science Center at San Antonio)
view all 12 authors...
263Background: Barriers to safe delivery of oral chemotherapy in a safety net hospital population include lack of health insurance, delays in medication delivery, and language barriers. Baseline ch...
Source
#1Nathaniel R. Wilson (University of Texas Health Science Center at Houston)H-Index: 2
#2Andrew Wiele (University of Texas MD Anderson Cancer Center)H-Index: 3
Last. Christopher G. Wood (University of Texas MD Anderson Cancer Center)H-Index: 83
view all 12 authors...
Abstract null null Introduction null Renal medullary carcinoma (RMC) is a rare and lethal renal cell carcinoma characterized by the loss of tumor suppressor SMARCB1. Molecular profiling studies have suggested that RMC cells may be vulnerable to therapies that generate DNA damage, such as the combination of the nucleoside analog gemcitabine, and topoisomerase inhibitor doxorubicin. null null null Patients and Methods null We retrospectively analyzed the records of patients with RMC treated with g...
Source
#1Andrew W. Hahn (University of Texas MD Anderson Cancer Center)H-Index: 15
#2Paul V. Viscuse (University of Texas MD Anderson Cancer Center)H-Index: 2
Last. Padmanee Sharma (University of Texas MD Anderson Cancer Center)H-Index: 71
view all 14 authors...
Source
#1Andrew Wiele (University of Texas MD Anderson Cancer Center)H-Index: 3
#2Tharakeswara K. Bathala (University of Texas MD Anderson Cancer Center)H-Index: 9
Last. Nizar M. Tannir (University of Texas MD Anderson Cancer Center)H-Index: 72
view all 11 authors...
Introduction Lenvatinib (Len) plus everolimus (Eve) is an approved therapy for metastatic renal cell carcinoma (mRCC) after first-line vascular endothelial growth factor receptor-tyrosine kinase inhibitors (VEGFR-TKI), but limited data exist on the efficacy of Len +/- Eve after progression on immune checkpoint inhibitors (ICI) and VEGFR-TKI. Methods We retrospectively reviewed the records of patients with mRCC at our institution who were treated with Len +/- Eve after ICI and VEGFR-TKI. A blinde...
Source
#1Andrew Wiele (University of Texas MD Anderson Cancer Center)H-Index: 3
#2Devaki Shilpa Surasi (University of Texas MD Anderson Cancer Center)H-Index: 1
Last. Pavlos Msaouel (University of Texas MD Anderson Cancer Center)H-Index: 29
view all 14 authors...
PURPOSE To assess the efficacy and safety of bevacizumab plus erlotinib in patients with RMC. METHODS We retrospectively reviewed the records of patients with RMC treated with bevacizumab plus erlotinib at our institution. RESULTS Ten patients were included in the study. Two patients achieved a partial response (20%) and seven patients achieved stable disease (70%). Tumor burden was reduced in seven patients (70%) in total, and in three out of five patients (60%) that had received three or more ...
Source
#1Andrew Wiele (University of Texas MD Anderson Cancer Center)H-Index: 3
#2Devaki Shilpa Surasi (University of Texas MD Anderson Cancer Center)H-Index: 1
Last. Pavlos Msaouel (University of Texas MD Anderson Cancer Center)H-Index: 29
view all 13 authors...
303Background: RMC is a rare and highly aggressive malignancy with a median overall survival (OS) of only 13 months from diagnosis. RMC is thought to be completely refractory to the targeted therap...
Source
#1Nathaniel R. Wilson (University of Texas Health Science Center at Houston)H-Index: 2
#2Andrew Wiele (University of Texas MD Anderson Cancer Center)H-Index: 3
Last. Pavlos Msaouel (University of Texas MD Anderson Cancer Center)H-Index: 29
view all 11 authors...
324Background: Renal medullary carcinoma (RMC) is one of the most lethal renal cell malignancies with a median overall survival (OS) of only 13 months from diagnosis (Shah et al. BJU Int., 2017). R...
Source
#1Leah K. Shaw (University of Texas MD Anderson Cancer Center)
#2Andrew Wiele (University of Texas MD Anderson Cancer Center)H-Index: 3
Last. Pavlos Msaouel (University of Texas MD Anderson Cancer Center)H-Index: 29
view all 5 authors...
Abstract Targeting the programmed cell death protein-1 (PD-1) and cytotoxic T-lymphocyte associated protein-4 (CTLA-4) pathways using the combination immune checkpoint inhibitors (ICI) nivolumab and ipilimumab is an approved frontline therapy for patients with metastatic clear-cell renal cell carcinoma (mccRCC). Certain populations pose clinical challenges due to exclusion from large clinical trials that established the safety and efficacy of these treatments, including patients with end stage r...
Source
Source
This website uses cookies.
We use cookies to improve your online experience. By continuing to use our website we assume you agree to the placement of these cookies.
To learn more, you can find in our Privacy Policy.